Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Cardiogen

A Khavinson-series tetrapeptide tested on rat heart-tissue explants in a dish; not the CardioGen-82 heart-imaging agent, and not tested on living hearts.

L1Theory onlyNot approved for this use
Full profile

Epitalon

Longevity claims built on an old, narrow and largely unreplicated body of research.

L1Theory onlyResearch / unapproved supply
Full profile

How far human research has progressed

Cardiogen

Preclinical (organotypic tissue culture)

Epitalon

Preclinical and historical small-scale human reports

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Cardiogen

Not separately assessed; see the full profile.

Epitalon

Not separately assessed; see the full profile.

Human research context

Cardiogen

Preclinical (organotypic tissue culture)

Epitalon

Preclinical and historical small-scale human reports

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Cardiogen

Strength of the human efficacy evidence1 of 100 evidence strength

Epitalon

Strength of the human efficacy evidence10 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Cardiogen

Strength of the animal and lab evidence10 of 100 evidence strength

Epitalon

Strength of the animal and lab evidence45 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Cardiogen

Strength of the human safety evidence2 of 100 evidence strength

Epitalon

Strength of the human safety evidence10 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Cardiogen

Check jurisdiction-specific details in the profile.

Not an approved medicine in any major jurisdiction. Sale as a 'research chemical' is a legal and supply-chain statement, not evidence of benefit or harm. Not to be confused with CardioGen-82 (rubidium-82 generator), an approved PET heart-imaging product that is unrelated to this peptide.

Epitalon

Check jurisdiction-specific details in the profile.

Not an approved medicine in major regions. Sold as a research compound. FDA has treated epitalon as a bulk substance raising significant safety risks for compounding; that listing status changed during 2026 and it was covered by FDA's July 2026 advisory committee review.

Common claims

Cardiogen

  • · Heart protection
  • · Cardiac anti-ageing

Epitalon

  • · Lengthens telomeres
  • · Extends human lifespan
  • · Restores pineal and circadian function

How settled our evidence rating is

Cardiogen

Very low confidence in ratingL1Theory only

Epitalon

Very low confidence in ratingL1Theory only

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Cardiogen

Not established. Increased proliferation and reduced p53 in tissue culture are reasons for caution, not findings of risk.

Epitalon

Telomerase reactivation is a hallmark of many cancers, so deliberately activating it is a legitimate theoretical concern. There is no human evidence that Epitalon causes cancer — and no human evidence that it does not. Unknown is the accurate word.

What this adds up to, in plain English

Cardiogen

This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.

Epitalon

This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.